This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More

BOSTON ( TheStreet) -- More responses to my special midweek, all-Twitter version of the Biotech Stock Mailbag:

Make sure to also check out part 1 of the Twitter Mailbag, with answers to questions about Gilead Sciences, Chelsea Therapeutics, Onyx Pharma, BioSante, Dendreon and Titan Pharma.

@kevinmcgreevey: "How does $orex keep going up with that joke of a drug?"

I don't consider Orexigen Therapeutics' (OREX - Get Report) obesity drug Contrave to be a joke. Contrave is probably inferior to Vivus' (VVUS) Qnexa but it's better than Arena Pharmaceutical's (ARNA) lorcaserin, which isn't much more effective than placebo.

Don't forget, Contrave was the only obesity drug of the three to win a positive advisory panel vote last year. Lingering cardiovascular safety concerns was the outstanding issue that prevented FDA from approving it.

@pelion2001: "Dose of reality needed w/ OREX phase 2 interim min 2 yrs off + stock flying."

I'm surprised traders are surprised that Orexigen shares are moving higher -- up as much as 30% since last Thursday -- in sympathy with the positive panel vote on Vivus' Qnexa. Don't we see this type of speculative trading pattern all the time?

I agree with the sentiment that Orexigen's fate is not tied directly to Vivus or last week's panel decision, which means Orexigen's recent uptick is hard to justify on a fundamental basis. Be especially wary of the millions of low-priced warrants outstanding as a potential future dilutive event. The way I look at obesity drug stocks today, however, is that they trade more on sentiment than fundamentals and sentiment is surging positive. Maybe that will change if/when Vivus' Qnexa is approved and investors switch to shorting the launch.

@RFederer2: "Adam, any opinions on what AFFY does when (if) it gets approved? Is high teens a possibility?"

Admittedly, these are some very rough, back-of-envelope calculations, but I'd say Affymax (AFFY) at $10.50 and a $260 million enterprise value is pricing in about $200 million in peginesatide sales by 2015. At this point, I believe you need to be very bullish on the once-monthly anemia drug to justify a stock price in the high teens.

This is simplistic, but I split the current $2 billion dialysis market for anemia drugs into three equal buckets. The first bucket is controlled by Davita (DVA), which is basically locked up under contract to use Amgen's (AMGN) Epogen. I assume Affymax and its peginesatide marketing partner Takeda get no Davita business.

Fresenius (FMS) controls the second third of the anemia drug business. It also has a contract with Amgen to buy Epogen but the deal is non-exclusive. Can Affymax tap 20% of Fresenius' business? Sounds reasonable to me, which equates to about $130 million in peginesatide sales.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ASTM $3.53 3.22%
SPPI $6.27 0.80%
OREX $4.90 0.00%
AFFY $0.09 0.00%
AAPL $130.28 0.00%

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs